Physician profile
Simranjit Kaur Singh
NPI 1396164356
$12,349.11
in general payments reported to CMS, 2019-2025
37 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $708 · 2021: $626 · 2022: $2,549 · 2023: $2,184 · 2024: $2,770 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,160 · Education: $255 · Travel and Lodging: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,159.60 |
| Education | $254.97 |
| Travel and Lodging | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,914.32 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,412.39 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $948.45 | 2021-2025 | |
| Janssen Biotech, INC. | $941.73 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $866.01 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $690.36 | 2019-2025 | Benlysta |
| Ucb, INC. | $642.16 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $413.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.52 | 2020-2025 | Cyltezo, Ofev, Jascayd |
| Horizon Therapeutics Plc | $236.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $234.89 | 2021-2024 | Saphnelo |
| Fresenius Kabi USA, LLC | $230.69 | 2023-2025 | |
| Radius Health, INC. | $215.49 | 2020-2025 | Tymlos |
| Sobi, INC | $151.80 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $136.93 | 2022-2025 | Lupkynis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $129.39 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $128.39 | 2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $112.48 | 2022-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $78.01 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $72.18 | 2024-2025 | Acthar |
| Alvogen INC | $66.17 | 2024-2025 | Teriparatide |
| Sandoz INC. | $50.06 | 2024-2025 | Hyrimoz |
| Genzyme Corporation | $46.81 | 2019-2020 | |
| Organon LLC | $39.05 | 2024-2025 | Hadlima |
| Medexus Pharma, INC. | $38.98 | 2019 | |
| Merck Sharp & Dohme LLC | $34.91 | 2025 | Winrevair |
| Hikma Pharmaceuticals USA | $32.84 | 2019-2022 | |
| Octapharma USA, INC. | $32.38 | 2024-2025 | Octagam Immune Globulin (Human) |
| Fidia Pharma USA INC. | $28.02 | 2022-2024 | Hyalgan, Hymovis, Triluron |
| Scilex Pharmaceuticals INC. | $20.29 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.43 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.39 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.10 | 2019 | |
| Antares Pharma, INC. | $13.04 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.33 | 2022 | |
| Genentech USA, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simranjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.